Study Evaluating Safety of GSI 136 in Young and Elderly Japanese Males
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human study of GSI-136, a gamma-secretase inhibitor being developed for
the treatment of Alzheimer disease. This study will take place in Japan only and will provide
an initial assessment of the safety, tolerability, pharmacokinetics (PK), and
pharmacodynamics (PD) of GSI-136 after administration of ascending single oral doses to
healthy Japanese male subjects and healthy Japanese elderly male subjects.